Synthesis and Biological Activity of Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2-Aryl-Substituted Benzimidazoles

1997 ◽  
Vol 40 (26) ◽  
pp. 4199-4207 ◽  
Author(s):  
Thomas Roth ◽  
Marshall L. Morningstar ◽  
Paul L. Boyer ◽  
Stephen H. Hughes ◽  
Robert W. Buckheit, ◽  
...  
ChemInform ◽  
2010 ◽  
Vol 29 (20) ◽  
pp. no-no
Author(s):  
T. ROTH ◽  
M. L. MORNINGSTAR ◽  
P. L. BOYER ◽  
S. H. HUGHES ◽  
R. W. JUN. BUCKHEIT ◽  
...  

2007 ◽  
Vol 50 (17) ◽  
pp. 4003-4015 ◽  
Author(s):  
Marshall L. Morningstar ◽  
Thomas Roth ◽  
David W. Farnsworth ◽  
Marilyn Kroeger Smith ◽  
Karen Watson ◽  
...  

2006 ◽  
Vol 50 (8) ◽  
pp. 2772-2781 ◽  
Author(s):  
Zhijun Zhang ◽  
Michelle Walker ◽  
Wen Xu ◽  
Jae Hoon Shim ◽  
Jean-Luc Girardet ◽  
...  

ABSTRACT Mutations in and around the catalytic site of the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) are associated with resistance to nucleoside RT inhibitors (NRTIs), whereas changes in the hydrophobic pocket of the RT are attributed to nonnucleoside RT inhibitor (NNRTI) resistance. In this study, we report a novel series of nonnucleoside inhibitors of HIV-1, exemplified by VRX-329747 and VRX-413638, which inhibit both NNRTI- and NRTI-resistant HIV-1 isolates. Enzymatic studies indicated that these compounds are HIV-1 RT inhibitors. Surprisingly, however, following prolonged (6 months) tissue culture selection, this series of nonnucleoside inhibitors did not select NNRTI-resistant mutations in HIV-1 RT. Rather, four mutations (M41L, A62T/V, V118I, and M184V) known to cause resistance to NRTIs and two additional novel mutations (S68N and G112S) adjacent to the catalytic site of the enzyme were selected. Although the M184V mutation appears to be the initial mutation to establish resistance, this mutation alone confers only a two- to fourfold decrease in susceptibility to VRX-329747 and VRX-413638. At least two additional mutations must accumulate for significant resistance. Moreover, while VRX-329747-selected viruses are resistant to lamivudine and emtricitabine due to the M184V mutation, they remain susceptible to zidovudine, stavudine, dideoxyinosine, abacavir, tenofovir, and efavirenz. These results directly demonstrate that VRX-329747 and VRX-413638 are novel nonnucleoside inhibitors of HIV-1 RT with the potential to augment current therapies.


Author(s):  
Subramaniyan Arulmurugan ◽  
Helen P. Kavitha ◽  
Jasmine P. Vennila

Abstract:: Benzoxazole compounds have an important and broad range of biological activities. The benzoxazole and its substituted derivatives possess antimicrobial, antitumor, anti-inflammatory, antihistaminic, anti-parasitic, herbicidal, antiallergic, anti-helmintic, anti-tubercular, anticonvulsant, hypoglycaemic, HIV-1 reverse transcriptase inhibitor and insecticidal activities. It has also been shown to have binding affinity to Aβ42 fibrils. Such complex biological uses of benzoxazole compounds have inspired new efforts to find new derivatives with improved biological activity and different applications in the pharmaceutical industry. Outstanding the relevance of this structure, the purpose of this analysis is to highlight aspects published in recent years (2000-2020) on the chemistry and biological activity of benzoxazoles.


Sign in / Sign up

Export Citation Format

Share Document